RNA Therapeutics Market Size is expected to reach US$ 948 Million by 2031, Report by CoherentMI
Burlingame, Sept. 09, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, RNA Therapeutics Market is estimated to value at US$ 2.5 Million in the year 2024 and is anticipated to reach US$ 948 Million by 2031, at a CAGR of 68% during forecast period 2024-2031. RNA therapeutics utilizes RNA interference and antisense technologies for modulating gene expression using RNA molecules. RNA therapeutics provides treatments for hereditary disorders, cancer, and infectious diseases. RNAi therapeutics is considered as one of the most promising areas of modern drug discovery. This is due to its ability to treat previously undruggable disease targets through selective silencing of gene expressions. Pharmaceutical companies are actively investing in RNAi therapeutics research to develop novel treatments for various chronic diseases like cancer, cardiovascular disease, neurodegenerative disorders etc.
Market Report Scope:
| Report Coverage | Details |
| Market Revenue in 2024: | US$ 2.5 Million |
| Estimated Value by 2031: | US$ 948 Million |
| Growth Rate: | Poised to grow at a CAGR of 68% |
| Historical Data: | 2019–2023 |
| Forecast Period: | 2024–2031 |
| Forecast Units: | Value (USD Million/Billion) |
| Report Coverage: | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered: | By Type of Modality, By Type of Molecule |
| Geographies Covered: | Global |
| Growth Drivers: | • Increasing Prevalence of Chronic Diseases Demanding Advanced Therapies |
| • Growing Investments in RNA-based Research and Development | |
| Restraints & Challenges: | • High Cost and Complexity of RNA-based Therapeutics |
Market Dynamics:
The growing demand for precision medicine and increasing R&D investment are the major factors fueling the growth of the RNA therapeutics market. Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. It allows doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people. Thus, RNA therapeutics that offers highly targeted and personalized treatment is gaining more attention in the precision medicine domain. Furthermore, increasing funding from both private and public organizations has resulted in high investment in R&D by key market players, which is supporting the market growth.
Key Market Takeaways:
- The RNA therapeutics market size was valued at USD 2.5 billion in 2024 and is anticipated to witness a CAGR of 68% during the forecast period 2024-2031. This significant growth can be attributed to increasing success of mRNA vaccines and therapies in clinical trials.
- By type of modality, RNA Therapeutics segment dominated the market in 2024 due to higher adoption of personalized mRNA cancer vaccines and gene therapies. Within this segment, replicating RNA (repRNA) sub-segment is expected to grow at a higher pace owing to capabilities of self-amplification.
- Based on region, North America held the major share of RNA therapeutics market in 2024 due to strong presence of key pharma companies and favorable regulatory environment for novel drug development.
- The key players operating in the global RNA therapeutics market include Alphavax, Arcturus Therapeutics, Atyr Pharma and Gritstone Bio among others. Strategic collaborations between big pharma and biotech firms are helping further clinical development of different RNA molecules.
Market Trends:
RNA interference (RNAi) therapeutics holds promising potential to revolutionize the treatment of diseases. RNAi is an innate cellular mechanism involved in regulating gene expression. By exploiting this natural pathway with synthetic small interfering RNA (siRNA), it is possible to target and degrade specific messenger RNA (mRNA) molecules and thereby reduce the production of disease-associated proteins.
Several biopharmaceutical companies are engaged in developing RNAi therapeutics and have candidates in different stages of clinical trials for various diseases such as cancer, hepatitis, neurodegenerative diseases, and genetic disorders. For instance, Alnylam Pharmaceuticals commercialized the first-ever RNAi therapeutic called Onpattro in 2018, used for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Nucleoside-modified mRNA has gained attention as a safer and more sustainable approach for gene therapy compared to DNA or viral vectors. The non-integrating nature of mRNA makes it less likely to cause genomic alterations. Some companies such as Moderna, BioNTech, and CureVac are leveraging the potential of mRNA for delivering genetic instructions to produce therapeutic proteins inside patient cells.
Recent Developments:
- In February 2023, Tevard Biosciences partnered with Vertex Pharmaceuticals to develop tRNA-based therapies for Duchenne Muscular Dystrophy.
- In January 2024, Circular Genomics raised $8.3 million in series A funding for the world’s first circRNA-based clinical assay to improve depression treatment.
Get a detailed analysis on regions, market segments, and companies: https://www.coherentmi.com/industry-reports/rna-therapeutics-market
RNA Therapeutics Market Opportunities:
RNA Cell and Gene Therapy: RNA cell and gene therapy is one of the major market opportunities in the RNA therapeutics industry. RNA cell and gene therapy utilizes RNA-based molecules like mRNA and engRNA to target and modify specific cells and genes for treating various diseases. It offers more flexibility and safety compared to conventional gene therapy as RNA doesn't integrate into the host genome. Many biotech companies are developing innovative RNA cell and gene therapies for cancers, monogenic disorders, infectious diseases etc. For instance, Moderna is conducting clinical trials for personalized cancer mRNA vaccine and engRNA therapy for Fabry disease.
RNA Vaccines: RNA vaccines against infectious diseases and cancers have emerged as another big opportunity area. RNA vaccines help produce the immunogenic protein inside the body to elicit a strong immune response without the risk of infection. They can be designed and manufactured faster than conventional vaccines. Many players are developing self-amplifying mRNA vaccines for COVID-19, influenza, Zika virus etc. Biotech firms like CureVac, Translate Bio are also exploring RNA vaccines for various cancers. The success of COVID mRNA vaccines has further boosted interest and funding in this sector.
RNA Therapeutics Market Segmentation:
- By Type of Modality
- RNA Therapeutics
- RNA Vaccines
- By Type of Molecule
- Replicating RNA (repRNA)
- Self amplifying RNA (saRNA)
- Self activating RNA (sacRNA)
- Self activating mRNA (samRNA)
- Transfer RNA (tRNA)
Purchase Latest Edition of this Research Report @ https://www.coherentmi.com/industry-reports/rna-therapeutics-market/buynow
The research provides answers to the following key questions:
- What is the estimated growth rate of the market for the forecast period 2024-2031?
- What will be the market size during the estimated period?
- What are the key driving forces responsible for shaping the fate of the RNA Therapeutics market during the forecast period?
- Who are the major market vendors and what are the winning strategies that have helped them occupy a strong foothold in the RNA Therapeutics market?
- What are the prominent market trends influencing the development of the RNA Therapeutics market across different regions?
- What are the major threats and challenges likely to act as a barrier in the growth of the RNA Therapeutics market?
- What are the major opportunities the market leaders can rely on to gain success and profitability?
Key insights provided by the report that could help you take critical strategic decisions?
- Regional report analysis highlighting the consumption of products/services in a region also shows the factors that influence the market in each region.
- Reports provide opportunities and threats faced by suppliers in the RNA Therapeutics industry around the world.
- The report shows regions and sectors with the fastest growth potential.
- A competitive environment that includes market rankings of major companies, along with new product launches, partnerships, business expansions, and acquisitions.
- The report provides an extensive corporate profile consisting of company overviews, company insights, product benchmarks, and SWOT analysis for key market participants.
- This report provides the industry's current and future market outlook on the recent development, growth opportunities, drivers, challenges, and two regional constraints emerging in advanced regions.
Browse More Trending Reports:
Short-Acting Insulin Market: The short-acting insulin market is estimated to be valued at USD 9.5 Bn in 2024 and is expected to reach USD 13.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2031.
Knee Osteoarthritis Market: The knee osteoarthritis market is estimated to be valued at USD 11.7 Bn in 2024 and is expected to reach USD 30.01 Bn by 2031, growing at a compound annual growth rate (CAGR) of 12.5% from 2024 to 2031.
Clinical Trial Services Market: The clinical trial services market is estimated to be valued at USD 1.09 billion in 2024 and is expected to reach USD 2.75 billion by 2031, growing at a compound annual growth rate (CAGR) of 14.1% from 2024 to 2031.
Blastomycosis Treatment Market: The blastomycosis treatment market is estimated to be valued at USD 202 Mn in 2024 and is expected to reach USD 321.6 Mn by 2031, growing at a compound annual growth rate (CAGR) of 6.9% from 2024 to 2031.
Author of this marketing PR:
Priya Pandey is a dynamic and passionate PR writer with over three years of expertise in content writing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes writing contents and documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
About Us:
At CoherentMI, we are a leading global market intelligence company dedicated to providing comprehensive insights, analysis, and strategic solutions to empower businesses and organizations worldwide. Moreover, CoherentMI is a subsidiary of Coherent Market Insights Pvt Ltd., which is a market intelligence and consulting organization that helps businesses in critical business decisions. With our cutting-edge technology and experienced team of industry experts, we deliver actionable intelligence that helps our clients make informed decisions and stay ahead in today's rapidly changing business landscape.
Mr. Shah CoherentMI, U.S.: +1-650-918-5898 U.K: +44-020-8133-4027 Australia: +61-2-4786-0457 INDIA: +91-848-285-0837 Email: sales@coherentmi.com Website: https://www.coherentmi.com
© Copyright Globe Newswire, Inc. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire, Inc.
